Clinical Trials Logo

Food Hypersensitivity clinical trials

View clinical trials related to Food Hypersensitivity.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT04761835 Withdrawn - Food Allergy Clinical Trials

STEP-IT-UP - Peanut Allergy Study for Infants

Start date: November 1, 2021
Phase: Phase 2
Study type: Interventional

Multicenter randomized (1:1) trial of strict avoidance versus sub-threshold dietary introduction of peanut in peanut allergic infants 4-14 months of age who react at a minimum cumulative dose of at least 430 mg of peanut protein at initial oral food challenge (OFC) for 12 months, followed by cross-over to sub-threshold dietary introduction of peanut in those randomized initially to avoidance.

NCT ID: NCT04200989 Withdrawn - Food Allergy Peanut Clinical Trials

Novel Treatment for Patients With Peanut Allergy: Intralymphatic Immunotherapy

Start date: March 1, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

Use of three intralymphatic injections of peanut allergen one month apart to induce tolerance to peanut in peanut allergic people.

NCT ID: NCT03089476 Withdrawn - Atopic Dermatitis Clinical Trials

Evaluating Skin Barrier Dysfunction in Infants at High Risk of Atopy

Start date: September 30, 2017
Phase: N/A
Study type: Interventional

It is hypothesized that food allergy is preceded by atopic dermatitis (AD), due to a disruption of skin barrier which can predispose one to food sensitization through the skin. The central hypothesis is that increased transepidermal water loss (TEWL) assessment and skin tape strip analysis (STS) of lipid and filaggrin breakdown products will be predictive markers for the development of AD. Additionally, the associated changes in TEWL and STS will further improve the identification of infants at risk of early food sensitization, compared to family history alone.

NCT ID: NCT02286999 Withdrawn - Atopic Dermatitis Clinical Trials

Probiotic Supplementation in Breastfed Newborn Infants

Start date: October 2015
Phase: Phase 1
Study type: Interventional

The purpose of this study is to investigate the dose of a probiotic supplement (Bifidobacterium longum subsp. infantis) required to achieve predominant gut colonization in healthy newborn, breastfed infants. The study will also examine whether supplementation with this probiotic can reduce the chance of developing eczema and food allergies in enrolled infants.

NCT ID: NCT00736112 Withdrawn - Clinical trials for Food Hypersensitivity

Food Allergy - Tubes - Adenoids (FATA) Trial

FATA
Start date: October 2008
Phase: N/A
Study type: Interventional

The questioned proposed by this study is one of treatment: "To what extent does simultaneous BMT (Bilateral Myringotomy with Tympanostomy Tubes), adenoidectomy, and diagnosis/avoidance of food allergy affect the frequency of recurrent otitis media (ROM) versus the standard academy approach (tube insertions only) to chronic otitis media with effusion; furthermore, are adenoids a factor in OME or is food allergy diagnosis and treatment able to significantly prevent ROM after the tubes fall out?" The trial seeks to provide evidence that the treatment for Chronic OME in children should involve surgical procedures (BMT +/- adenoidectomy), as well, as a food allergy work-up and subsequent avoidance of the offending foods in order to significantly decrease ROM. To answer this question, a prospective, randomized controlled trial needs to be conducted. Since a majority of OME patients are from the pediatric population, parental consent must be obtained. Subjects in our study will initially present to the clinic with otitis media symptoms and diagnostic tests such as a tympanogram, otoscopy, and history of recurrent otitis media will be obtained. Once the surgical decision for bilateral myringotomy and tympanostomy tubes has been made, parents will be informed about the trial. The standard protocol for children presenting with initial Chronic OME is to perform a BMT. Therefore, data from the control group (Group 1) will be obtained from faculty ENT who follow the academy's recommendations. Data from Group 2 and 3 will be collected from other ENT faculty members, including the faculty co-investigator who will perform the BMT and obtain a food allergy blood draw at the time of surgery. The study's faculty co-investigator will describe food avoidance techniques to post-op patients from Groups 2 and 3. Patients with previous adenotonsillar surgery or placement of tympanostomy tubes will not be enrolled in the study. The incidence of ROM episodes in all trial groups will be recorded.